Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2012-11-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD008079.pub2PMID 23152253PMCID PMC6485963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.

  2016cited by this paper
• Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in

  2013cited by this paper
• Alemtuzumab for patients with chronic lymphocytic leukaemia.

  2012cited by this paper
• Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients

  2012cited by this paper
• High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.

  2012cited by this paper
• A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

  2012cited by this paper
• A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase.

  2011cited by this paper
• Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

  2011cited by this paper
• Adverse effects of biologics: a network meta-analysis and Cochrane overview.

  2011cited by this paper
• Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy

  2011cited by this paper
• Chapter 10: Addressing reporting biases

  2011cited by this paper
• Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

  2011cited by this paper
• A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

  2011cited by this paper
• Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.

  2011cited by this paper
• Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

  2011cited by this paper
• Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

  2011cited by this paper
• Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.

  2011cited by this paper
• Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment

  2011cited by this paper
• Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

  2011cited by this paper
• Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

  2011cited by this paper
• Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study

  2011cited by this paper
• Ofatumumab

  2010cited by this paper
• Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience

  2010cited by this paper
• Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial

  2010cited by this paper
• The future of CD20 monoclonal antibody therapy in B-cell malignancies

  2010cited by this paper
• Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.

  2010cited by this paper
• Pentostatin and rituximab therapy for previously untreated patients with B‐cell chronic lymphocytic leukemia

  2010cited by this paper
• Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

  2010cited by this paper
• Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

  2010cited by this paper
• High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia

  2010cited by this paper
• New agents for the treatment of genetically high-risk chronic lymphocytic leukemia

  2010cited by this paper
• Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

  2010cited by this paper
• A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis

  2010cited by this paper
• Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

  2010cited by this paper
• Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial

  2010cited by this paper
• Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies.

  2009cited by this paper
• Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.

  2009cited by this paper
• Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

  2009cited by this paper
• Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901

  2009cited by this paper
• Long-Term Health Outcomes and Costs Associated with the Use of Rituximab in Combination with fludarabine and Cyclophosphamide (R-FC) in the Treatment of relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) in Poland.

  2009cited by this paper
• Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab

  2009cited by this paper
• Comparative Efficacy of First Line Therapies for Chronic Lymphocytic Leukemia: a Systematic Review and Meta-Analyses.

  2009cited by this paper
• FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

  2009cited by this paper
• Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL).

  2009cited by this paper
• Higher Doses of Rituximab May Be Required for Patients with CLL as Compared to NHL Based On Population Pharmacokinetic (PK) Modeling.

  2009cited by this paper
• Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.

  2009cited by this paper
• Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

  2009cited by this paper
• Alemtuzumab for chronic lymphocytic leukaemia

  2009cited by this paper
• Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

  2009cited by this paper
• TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

  2009cited by this paper
• RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  2009cited by this paper
• An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

  2009cited by this paper
• Dasatinib induces a response in chronic lymphocytic leukemia.

  2009cited by this paper
• A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

  2009cited by this paper
• Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

  2009cited by this paper
• Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.

  2009cited by this paper
• Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.

  2009cited by this paper
• Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

  2009cited by this paper
• Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia.

  2009cited by this paper
• Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.

  2009cited by this paper
• Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

  2009cited by this paper
• Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?

  2009cited by this paper
• Quality-Adjusted Survival (Q-TWiST) Analysis of Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia Treated with Rituximab Plus Fludarabine and Cyclophosphamide (R-FC) Versus FC Alone.

  2009cited by this paper
• Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.

  2008cited by this paper
• Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

  2008cited by this paper
• Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first‐line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

  2008cited by this paper
• Chapter 16: Special Topics in Statistics

  2008cited by this paper
• Chapter 8: Assessing risk of bias in included studies

  2008cited by this paper
• Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

  2008cited by this paper
• Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

  2008cited by this paper
• Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial

  2008cited by this paper
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

  2008cited by this paper
• Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia

  2008cited by this paper
• Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

  2008cited by this paper
• Chapter 9: Analysing Data and Undertaking Meta-Analyses

  2008cited by this paper
• Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia

  2008cited by this paper
• ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response.

  2008cited by this paper
• Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

  2008cited by this paper
• Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

  2007cited by this paper
• Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia

  2007cited by this paper
• Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

  2007cited by this paper
• Practical methods for incorporating summary time-to-event data into meta-analysis

  2007cited by this paper
• Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

  2007cited by this paper
• Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

  2007cited by this paper
• Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone (PCRM): A New Highly Active Regimen for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with PCR or FCR.

  2007cited by this paper
• Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).

  2007cited by this paper
• NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

  2007cited by this paper
• Placebo

  2007cited by this paper
• Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

  2006cited by this paper
• Purine antagonists for chronic lymphocytic leukaemia.

  2006cited by this paper
• The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201

  2006cited by this paper
• A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine‐based regimens

  2006cited by this paper
• Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

  2006cited by this paper
• Impact of Different Chemotherapy Regimen in Comorbid Patients with Advanced Chronic Lymphocytic Leukemia: Metaanalysis of Two Phase-III-Trials of the German CLL Study Group.

  2006cited by this paper
• Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

  2005cited by this paper

• Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era

  2023influential citation
• Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins.

  2023cites this paper
• Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using A Semi-Markovian Model Approach in R.

  2022cites this paper
• Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis

  2022cites this paper
• Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

  2021influential citation
• Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia

  2021cites this paper
• The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

  2021cites this paper
• Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

  2021cites this paper
• Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

  2019cites this paper
• Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies.

  2019cites this paper
• Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders

  2019cites this paper
• Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials

  2019cites this paper
• Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience.

  2019cites this paper
• Lymphoma of the female genital tract: a clinicopatholngical analysis of 25 cases.

  2019influential citation
• A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer

  2018cites this paper
• Altered expression of MALAT1 lncRNA in chronic lymphocytic leukemia patients, correlation with cytogenetic findings

  2018cites this paper
• Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

  2018cites this paper
• Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis

  2017cites this paper
• Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment

  2017cites this paper
• Myeloid p38 MAPK signaling in intestinal homeostasis, inflammation and tumorigenesis = Señalización por la MAPK p38 de células mieloides en la homeostasis, inflamación y tumorogénesis intestinal

  2017cites this paper
• Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients

  2016cites this paper
• CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice

  2016cites this paper
• Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy

  2016cites this paper
• Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data

  2016cites this paper
• Cytokine-like 1 Chemoattracts Monocytes/Macrophages via CCR2

  2016cites this paper
• Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia

  2016cites this paper
• Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy.

  2016cites this paper
• Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission

  2016cites this paper
• Enhanced production of secretory glycoprotein VSTM1-v2 with mouse IgGκ signal peptide in optimized HEK293F transient transfection.

  2016cites this paper
• An overview of the diagnosis and management of immunoglobulin G4–related disease

  2016cites this paper
• Investigation of HIV cure strategies in vivo in BLT humanized mice

  2016cites this paper
• Patologi Targeting chronic lymphocytic leukemia cells using anti-ROR 1 monoclonal antibodies and small molecule inhibitors

  2015cites this paper
• Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen

  2015cites this paper
• CME Information: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

  2015cites this paper
• Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.

  2015cites this paper
• Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

  2015cites this paper
• Novel and emerging targeted-based cancer therapy agents and methods

  2015cites this paper
• Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)

  2015cites this paper
• Effectiveness, safety and costs of orphan drugs: an evidence-based review

  2015cites this paper
• Substytucja immunoglobulin u chorych na przewlekłą białaczkę limfocytową i szpiczaka plazmocytowego

  2015cites this paper
• Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies

  2014cites this paper
• Ibrutinib, Obinutuzumab, Idelalisib, and Beyond: Review of Novel and Evolving Therapies for Chronic Lymphocytic Leukemia

  2014cites this paper
• Cutaneous Lymphoid Infiltrates in Patients Receiving Biologic Modifiers

  2014cites this paper
• treatment strategies Signaling the end of chronic lymphocytic leukemia: new frontline

  2014cites this paper
• Immune Compromise Associated with Biologics

  2014cites this paper
• Incorporating targeted agents into future therapy of chronic lymphocytic leukemia.

  2014cites this paper
• Author ' s Accepted Manuscript Incorporating targeted agents into future therapy of CLL

  2014cites this paper
• A chemotherapy-free future? Novel treatment strategies for chronic lymphocytic leukemia

  2014cites this paper
• Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?

  2014cites this paper
• Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.

  2014influential citation
• Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.

  2013cites this paper
• Disseminated toxoplasmosis in non-allografted patients with hematologic malignancies: report of two cases and literature review

  2013cites this paper
• Issue Highlights—July 2013

  2013cites this paper
• Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts

  2013influential citation
• Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.

  2013cites this paper
• Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

  2013cites this paper
• Biomedicines as Adverse Event Inducers

  2013cites this paper
• B cell-regulated immune responses in tumor models and cancer patients

  2013cites this paper
• Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

  2013cites this paper
• Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials

  2013cites this paper
• Preparation and characterization of monoclonal antibodies against VSTM1.

  2013cites this paper
• Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.

  2013cites this paper
• Cancer Immunotherapy Comes of Age

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Running title: Rituximab plus Nutlin-3 loaded nanoparticles

  2013cites this paper
• Radionuclide antibody-conjugates, a targeted therapy towards cancer.

  2013cites this paper
• Alemtuzumab for patients with chronic lymphocytic leukaemia.

  2012cites this paper